Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
Patent Number: 6841386
Date of First Priority Issue: Tuesday April 10th, 2001
Date Issued: Tuesday January 11th, 2005
Assignee: Viacell, Inc. (Worcester, MA)
Inventors: Kraus, Morey (Jefferson, MA); Deng, Hongkui (Framingham, MA); Liu, Liqin (Framingham, MA)
From Class: Differentiation
Comments: No comments
Insulin like growth factor (IGF) is involved in numerous biological activities. The basis of this patent is that IGF possesses some differentiation inducing activity for CD34+ CD38- hematopoietic stem cells. The ability of stem cells to be expanded ex vivo depends on not allowing said cells to differentiate.
This patent teaches that blocking IGF signalling can inhibit hematopoietic stem cell differentiation. Specifically, the patent provides IGF-receptor binding protein-3 as a useful protein for inhibiting hematopoietic stem cell differentiation.
View this patent on the USPTO website.
Added to StemCellPatents.com on Monday October 16th, 2006
Social & Bookmarking:
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.